



Imaging and Liquid Biopsy Biomarkers for Cancer Diagnosis and Treatment

Guest Editors:

Dr. Wen Li

Department of Radiology and
Biomedical Imaging, University of
California, 550 16th Street, San
Francisco, CA 94158, USA

Dr. Mark Jesus M. Magbanua

Department of Laboratory
Medicine, University of California,
2340 Sutter Street, San Francisco,
CA 94115, USA

Deadline for manuscript
submissions:

31 August 2024

Message from the Guest Editors

Dear Colleagues,

Biomarkers are essential for cancer diagnosis and treatment. Imaging and liquid biopsy are both noninvasive methods that can be used to extract quantitative biomarkers repeatedly. A liquid biopsy involves testing blood and other bodily fluids. Radiomics and machine learning (ML)/ deep learning (DL) methods have been developed to study tumor heterogeneity. Imaging focuses on the tumor extent and heterogeneity measurement, while liquid biopsy detects tumor-derived molecules in circulation. In this Special Issue, we are interested in manuscripts that report work combining both imaging and liquid biopsy to diagnosis or treat cancer. Imaging modalities include magnetic resonance imaging (MRI), X-Ray imaging, computed tomography (CT), ultrasound, and nuclear medicine scans. The liquid biopsy includes tests that can evaluate circulating tumor cells (CTC), disseminated tumor cells (DTC), and circulating tumor DNA or RNA (ctDNA, ctRNA). We welcome original research articles or comprehensive review articles focusing on the combination of quantitative imaging and liquid biopsy biomarkers for cancer detection, staging, prognosis, or monitoring treatment response.





an Open Access Journal by MDPI

Editor-in-Chief

Prof. Dr. Samuel C. Mok

Department of Gynecologic
Oncology and Reproductive
Medicine, The University of Texas
MD Anderson Cancer Center,
Houston, TX 77030, USA

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Author Benefits

Open Access: free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility: indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank: JCR - Q1 (Oncology) / CiteScore - Q1 (Oncology)

Contact Us

Cancers Editorial Office
MDPI, St. Alban-Anlage 66
4052 Basel, Switzerland

Tel: +41 61 683 77 34
www.mdpi.com

mdpi.com/journal/cancers
cancers@mdpi.com
[X@Cancers_MDPI](https://twitter.com/Cancers_MDPI)